Logo

UPC

Universe Pharmaceuticals Inc.

UPC

Universe Pharmaceuticals Inc. • NASDAQ
$3.90 ▲ 4.56% (+0.17)
Market Cap $2.20 M
52w High $197.20
52w Low $2.51
Dividend Yield 0%
P/E -0.01
Volume 8.36K
Outstanding Shares 563.34K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $9.153M ▼ $5.491M ▼ $-3.285M ▼ -35.888% ▼ $-944.4 ▼ $-2.886M ▼
Q4-2024 $10.14M ▼ $9.107M ▲ $4.374M ▲ 43.137% ▲ $719.79 ▲ $4.694M ▲
Q2-2024 $12.884M ▼ $4.985M ▼ $-13.101M ▼ -101.685% ▼ $-2.156K ▼ $-12.051M ▼
Q4-2023 $13.842M ▼ $7.739M ▲ $-5.448M ▼ -39.357% ▼ $-919.74 ▼ $-3.806M ▼
Q2-2023 $18.467M $5.865M $-715.427K -3.874% $-120.79 $591.277K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $47.273M ▲ $80.667M ▲ $25.482M ▲ $55.185M ▲
Q4-2024 $29.498M ▲ $67.953M ▲ $22.45M ▼ $45.503M ▲
Q2-2024 $11.389M ▼ $49.431M ▼ $22.687M ▲ $26.744M ▼
Q4-2023 $18.504M ▼ $53.287M ▼ $13.754M ▼ $39.533M ▼
Q2-2023 $26.269M $70.368M $23.242M $47.127M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.285M ▼ $2.561M ▲ $-132.737K ▲ $16.398M ▼ $17.775M ▼ $2.464M ▲
Q4-2024 $4.374M ▲ $-7.077M ▼ $-293.629K ▼ $27.887M ▲ $20.636M ▲ $-7.372M ▼
Q2-2024 $-13.101M ▼ $-2.43M ▲ $-67.656K ▼ $6.068M ▲ $3.576M ▲ $-2.497M ▲
Q4-2023 $-5.448M ▼ $-3.64M ▼ $-43.523K ▼ $-3.472M ▼ $-7.669M ▼ $-3.684M ▼
Q2-2023 $-715.427K $4.799M $-646 $2.081M $7.243M $4.798M

Five-Year Company Overview

Income Statement

Income Statement Universe Pharmaceuticals is operating on a very small revenue base, and sales have been drifting down each year since listing. The company moved from a small profit in its first reported year to flat results, and now to recurring losses. Gross margins remain positive, but the scale of the business is too small to cover its overhead. Earnings per share look extremely volatile, but this is mostly driven by repeated reverse stock splits rather than big swings in the underlying business. Overall, the income statement shows a shrinking, loss‑making operation with no clear sign yet of a turnaround in growth or profitability.

Balance Sheet

Balance Sheet The balance sheet is modest in size, with a small pool of total assets and a limited but meaningful cash cushion. The company carries only a small amount of debt, and shareholder equity is still positive, which means it is not over‑leveraged. However, equity has been edging down as losses accumulate, indicating that financial resources are being slowly eroded. The balance sheet looks simple and not heavily burdened by obligations, but it also highlights how limited the company’s financial firepower is if it wants to invest, expand, or withstand a prolonged period of weak performance.

Cash Flow

Cash Flow Cash flow from the core business hovers around breakeven to slightly negative, which suggests the company is not consistently generating surplus cash from its day‑to‑day operations. Free cash flow has also been slightly negative in recent years, meaning that even modest investment needs are not being fully covered by internal cash generation. This puts more pressure on the existing cash balance and, over time, can force the company to either cut back on spending or find outside funding. Overall, cash flow trends point to a fragile financial position that leaves little room for missteps.

Competitive Edge

Competitive Edge Universe Pharmaceuticals occupies a niche in traditional Chinese medicine focused on elderly patients, a demographic that is growing in China. Its strengths are its specialization in this segment, an established distribution network across the country, and familiarity with culturally accepted TCM products. It also acts as both a manufacturer of its own branded products and a distributor for third‑party items, which broadens its offering. On the other hand, it competes in a crowded and highly competitive market, faces regulatory and pricing pressures, and its recent revenue decline suggests its competitive footing may be weakening rather than strengthening. Its relatively small scale compared with larger pharmaceutical peers is another constraint.

Innovation and R&D

Innovation and R&D The picture on innovation is unclear. Company materials reference a sizable patent portfolio and a blend of traditional Chinese medicine with modern biomedical techniques, but independent databases do not show much in the way of protected medical technology. There is little public detail on truly differentiated products, clinical data, or a future development pipeline. Recent communications have focused more on share consolidations and listing compliance than on research milestones. Taken together, this suggests that the company may be relying mainly on existing, approved TCM products and distribution capabilities, with limited visible investment in breakthrough R&D or clearly defined next‑generation offerings.

Summary

Universe Pharmaceuticals is a small, niche TCM player with a focus on elderly patients and a reasonably established distribution network inside China. Financially, the business has been shrinking, with declining revenue, recurring losses, and only thin, sometimes negative cash generation. The balance sheet still shows positive equity and some cash, but resources are modest and being gradually drawn down by ongoing losses. Strategically, the company’s main advantages are its niche focus and distribution reach, but these are offset by its small scale, intense competition, and limited transparency around innovation and future products. The key uncertainty is whether management can stabilize and grow the core business while improving visibility into its R&D and long‑term strategy.